

World Journal of *Gastroenterology*

World J Gastroenterol 2022 March 7; 28(9): 881-975



REVIEW

- 881 Innate and adaptive immune escape mechanisms of hepatitis B virus
Zhao HJ, Hu YF, Han QJ, Zhang J

MINIREVIEWS

- 897 Dualistic role of platelets in living donor liver transplantation: Are they harmful?
Liang C, Takahashi K, Furuya K, Ohkohchi N, Oda T
- 909 Applications of endoscopic ultrasound elastography in pancreatic diseases: From literature to real life
Conti CB, Mulinacci G, Salerno R, Dinelli ME, Grassia R

ORIGINAL ARTICLE**Basic Study**

- 918 Cystic fibrosis transmembrane conductance regulator prevents ischemia/reperfusion induced intestinal apoptosis *via* inhibiting PI3K/AKT/NF- κ B pathway
Dong ZW, Liu H, Su FF, Fan XZ, Zhang Y, Liu P

Retrospective Cohort Study

- 933 Sex-based differences in histology, staging, and prognosis among 2983 gastric cancer surgery patients
Choi Y, Kim N, Kim KW, Jo HH, Park J, Yoon H, Shin CM, Park YS, Lee DH, Oh HJ, Lee HS, Park YS, Ahn SH, Suh YS, Park DJ, Kim HH, Kim JW, Kim JW, Lee KW, Chang W, Park JH, Lee YJ, Lee KH, Kim YH

Retrospective Study

- 948 Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma
Liu ZP, Chen WY, Zhang YQ, Jiang Y, Bai J, Pan Y, Zhong SY, Zhong YP, Chen ZY, Dai HS

Observational Study

- 961 Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study
Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MDC, Peticollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L

LETTER TO THE EDITOR

- 973 Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough
Yan H, Yu TN

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Shozo Osera, MD, PhD, Chief Physician, Department of Gastroenterology, Saku Central Hospital Advanced Care Center, 3400-28, Nakagomi, Saku 385-0051, Nagano, Japan. shou0122@hotmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Ze-Mao Gong*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

March 7, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough

Han Yan, Tu-Nan Yu

Specialty type: Gastroenterology and Hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Herold M, Mohamed SY

Received: October 31, 2021

Peer-review started: October 31, 2021

First decision: December 12, 2021

Revised: January 3, 2022

Accepted: January 29, 2022

Article in press: January 29, 2022

Published online: March 7, 2022



Han Yan, Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China

Tu-Nan Yu, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China

Corresponding author: Tu-Nan Yu, MD, PhD, Doctor, Statistician, Surgeon, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 Qingchun East Road, Hangzhou 310016, Zhejiang Province, China. 3314006@zju.edu.cn

Abstract

There remains a persistent unmet need to detect the disease nonresponse (nonDR) subgroup before adjuvant therapy in synchronous liver metastasis patients with colorectal cancer. Ma's radiomics-clinical nomogram shows potential for the early detection of nonDR subgroups, but it is not good enough owing to at least three limitations, which we address in this letter to the editor. First, the study did not explore RAS/BRAF mutations, HER2 amplifications, *etc.* to complement the current nomogram. Second, the nomogram was not validated in left- and right-sided tumors separately. Third, the most critical factor for determining the success of adjuvant therapy should be resectability rather than tumor size shrinkage, which was used in the study.

Key Words: Synchronous liver metastasis; Colorectal cancer; Radiomics

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: There remains a persistent unmet need to detect the disease nonresponse subgroup before adjuvant therapy in synchronous liver metastasis patients with colorectal cancer. Ma's radiomics-clinical nomogram is currently not good enough, as the study did not explore the statuses of certain tumor genes, did not validate the nomogram in left- and right-sided tumors separately, and used tumor size shrinkage rather than resectability to judge the success of adjuvant therapy.

Citation: Yan H, Yu TN. Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough. *World J Gastroenterol* 2022; 28(9): 973-975

URL: <https://www.wjgnet.com/1007-9327/full/v28/i9/973.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v28.i9.973>

TO THE EDITOR

Ma *et al*[1] recently published a novel study investigating the effect of magnetic resonance imaging-radiomics in predicting chemotherapeutic response in synchronous liver metastasis (SLM) patients with colorectal cancer (CRC). They proposed a radiomics-clinical nomogram (including the radiomics score, CA19-9, and lymphatic staging) with an area under the curve of 0.809, suggesting high predictive accuracy.

We congratulate the authors for their creative work, as in decision-making for adjuvant therapy in CRC patients with unresectable SLM, there remains a persistent unmet need to detect the disease nonresponse (nonDR) subgroup. Early detection of nonDR patients, aided by the radiomics-clinical nomogram of Ma's study, could result in substantial changes in subsequent therapeutic plans. For instance, in nonDR cases, more aggressive regimens could be applied instead of the frequently used FOLFOX or CAPOX, such as administration of bevacizumab to inhibit vascular endothelial growth factor or pembrolizumab for immunotherapy. Local regional therapies, including radiofrequency ablation and transcatheter arterial chemoembolization, could also be considered to treat SLM.

However, despite the aforementioned merit, there are at least three limitations to be discussed concerning this nomogram. First, although the authors explored tumor biomarkers, including CEA and CA19-9, to complement radiomics, the statuses of some critical tumor genes (*e.g.*, RAS/BRAF mutations, HER2 amplification, and MSI/MMR status) were not examined, despite the relevant recommendation in the latest National Comprehensive Cancer Network guideline[2]. Second, it is noteworthy that the biological behaviors of CRC differed depending on the anatomical location[3]. For instance, right-sided CRC patients with SLM were unlikely to respond to cetuximab and panitumumab as first-line therapy. Therefore, the performance of Ma's nomogram should be validated in right- and left-sided CRC separately. Last but not least, the most critical limitation was that the success of adjuvant therapy in CRC patients with SLM should be resectability, rather than tumor size shrinkage used in this study.

In conclusion, in CRC patients with SLM, Ma's radiomics-clinical nomogram shows potential for clinical utilization. However, it is currently not good enough.

FOOTNOTES

Author contributions: All authors helped to prepare this manuscript; Yan H and Yu TN contributed to manuscript writing, drafting conception and design.

Conflict-of-interest statement: All authors declare that there are no conflicts of interest, and there was no fund supporting this manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Han Yan 0000-0001-8189-6678; Tu-Nan Yu 0000-0003-0866-3178.

S-Editor: Gong ZM

L-Editor: A

P-Editor: Gong ZM

REFERENCES

- 1 Ma YQ, Wen Y, Liang H, Zhong JG, Pang PP. Magnetic resonance imaging-radiomics evaluation of response to chemotherapy for synchronous liver metastasis of colorectal cancer. *World J Gastroenterol* 2021; 27: 6465-6475 [PMID: 34720535 DOI: 10.3748/wjg.v27.i38.6465]

- 2 **Yang SY**, Cho MS, Kim NK. Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. *Expert Rev Anticancer Ther* 2018; **18**: 351-358 [PMID: [29458272](#) DOI: [10.1080/14737140.2018.1442217](#)]
- 3 **National Comprehensive Cancer Network**. Colon Cancer (Version 3.2021). [Accessed October 18, 2021]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

